North even eat two enterprises are still not all the medicine proposed in Hong Kong to raise funds to push mergers and acquisitions

January 12, Shanghai Pharmaceutical Group Co., Ltd. (601607,SH) officially announced the acquisition of Citic Medicine and love Albert Medicine in Beijing. On the details of the acquisition, Lu Mingfang, chairman of the pharmaceutical group, said: "The holding of Citic pharmaceutical transactions amounted to 2.328 billion yuan, a total of 65% shares of Citic Medicine, is expected to complete the acquisition of all shares in March 2011." And in love Albert Pharmaceutical, medicine group has made 100% shares, acquisition progress has entered the consolidated report system.　　"The forecast data show: With the completion of the project, the" New medicine "can enter the first three markets in Beijing, the 2010 Beijing market is expected to contribute to the new medicine sales revenue of about 7 billion yuan, 2011 will reach 10 billion yuan.　　Medicine Group This "to the north" of the big move also stirred the domestic pharmaceutical market, will be the white-hot "merger and reorganization" to the depth. "For the two companies that have been bought, they will benefit from the improved product channels and high visibility of the group, which would be of great help to the growth of their performance," said Guofan, a researcher at CIC's pharmaceutical industry, to the daily economic news. "After the reorganization of the new medicine after the purchase as a hair originated in east China, the drug in the domestic pharmaceutical industry," the next City ", from it to become a national drug enterprise goal and a step closer. There are data show: the current business scope of Shanghai medicine mainly covers pharmaceutical research and development, manufacturing, distribution and retail, is a a-share motherboard market value of the largest industry-wide chain of pharmaceutical listed companies.　　As at December 3, 2010, the market value of the new medicine has reached $43.519 billion. Before the completion of the acquisition, the pharmaceutical group is mainly in east China market as the base. At present, Shanghai Medicine is the first in East China, the country's second largest pharmaceutical commercial enterprises. In the production of pharmaceutical links, medicine group sales scale ranked third in the industry.　　At the same time, in 2009, the East China market (accounting for the national pharmaceutical Market total of 40%), medicine Group Pharmaceutical distribution market share of 18%, in Shanghai, the market share of more than 50%, and has a large pharmacy, such as chain retail pharmacies more than 2000. Medicine Group "Acquisition + reorganization integration" the real force of the combined boxing, is starting from 2010. In March of that year, Shanghai Pharmaceutical completed a major asset reorganization, integration of the real group and medicine group pharmaceutical Business, to Shanghai Medicine for a single platform to achieve the overall listing.　　Subsequently, the medicine group has acquired Guangdong Zhongshan Pharmaceutical company, Fujian pharmaceutical company, Shandong merchants, such as 9 enterprises, the overall strength of its East China to further consolidate and enter the South China market. The drug acquisition of Citic Medicine, is seen as the new rehabilitation since the largest mergers and acquisitions, so that the group can further expand to Beijing, Tianjin and Hebei. According to the public data show: the acquisition of Citic Pharmaceutical main business in the Beijing market, in the local market share ranked third. Among them, the hospital net sales accounted for 70%, 2010 sale Income of more than 6 billion yuan. Together with this acquisition and the unveiling of the relatively small size of private enterprises love Albert,The total sales over 7 billion yuan.　　Medicine "merger of the war" into the white-hot is not difficult to see, the pharmaceutical group "to the north" behind the move, in order to build "in East China, South China, north China, the three major areas of the national pharmaceutical Distribution Network", with the old rivals really in the national scope of a higher. Medicine Group in the acquisition conference said: "The future of Medicine will be Beijing as a stronghold, further to Tianjin, Hebei and other north China to expand, the formation of Beijing as the core of the North China Pharmaceutical Distribution Network, thus the basic realization of the new national Pharmaceutical distribution network of the big pattern." "In this respect, Guofan said, pharmaceutical group in Beijing to set up Beijing representative office, can take Beijing as the core, began to Tianjin, the northeast giant strides forward, not only can and resources North Medicine launched close to hand-to-hand combat, can also promote its national layout of the pace of its competition in the domestic pharmaceutical circulation enterprises second place is critical.　　and the medicine group North is also its departure from the regional nature of drug Enterprises in East China, marking a large comprehensive pharmaceutical industry group's development goals and take a solid step. However, Guofan also said: "The pharmaceutical group North, although opened up a new road to external expansion, but its development will still be subject to the medicine group and the North China Resources Limited." "Compared to the pharmaceutical group, its" old rivals "and China Resources North Medicine group in the acquisition of the strength of the integration is not inferior. According to public Information: September 2009, the Chinese Medicine Group and the state-owned important backbone Enterprises, the largest supplier of vaccine and blood products suppliers in the joint reorganization of the health group; in China Resources North, 2010 China Resources Group successfully put the 100% Beijing Pharmaceutical Group's shares under its command, and thereafter,　　Henan Province, the second largest pharmaceutical business enterprise Love Health Medicine Logistics Co., Ltd. also joined China Resources Group, as the North Medical shares of the holding subsidiary.　　Facing the bright future competition is unusually white-hot, Lu Mingfang to the "daily economic news" that 2011 years of medicine will increase in the pharmaceutical industry, mergers and acquisitions and development efforts. It is noteworthy that Shanghai Medical said that the group is about to complete the initial public offering of H-shares, become the first a+h large pharmaceutical listed companies. "The overall financing scale will not be lower than that of the medicines, while the half of the H-share financing will be used for mergers. "Lu Mingfang points out.